William J. Sasiela
Esperion Therapeutics (United States)(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Cancer, Lipids, and Metabolism, Health Systems, Economic Evaluations, Quality of Life, Diabetes, Cardiovascular Risks, and Lipoproteins, Pharmaceutical Economics and Policy
Most-Cited Works
- → Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome(2018)3,374 cited
- → Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease(2005)1,330 cited
- → Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease(2017)850 cited
- → Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients(2023)800 cited
- → Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study(2012)731 cited
- → Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial(2014)409 cited
- → High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study(2003)405 cited
- → ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia(2017)325 cited
- → Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial(2019)322 cited
- → Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia(2019)239 cited